LQDA, US53635D2027

HC Wainwright lifts target for Liquidia stock from USD 58 to USD 65

Published on 10/20/2026 at 18:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

HC Wainwright lifts its target from USD 58 to USD 65 on October 15, 2026. Liquidia stock costs EUR 32.22 on October 20, 2026.

Target and reporting date

HC Wainwright raised its Liquidia target from USD 58.00 to USD 65.00 on October 15, 2026.
Liquidia reported USD 171.68 million in second-quarter 2026 revenue against a USD 168.48 million consensus estimate.
Liquidia stock costs EUR 32.22 at Lang & Schwarz on October 20, 2026 at 6:35 p.m. CEST.
Liquidia is estimated to report third-quarter 2026 results on November 2, 2026.

LQDA, US53635D2027, Illustration mit AI erstellt.

Liquidia Corporation stock trades at EUR 32.22 at Lang & Schwarz on October 20, 2026 at 6:35 p.m. CEST. HC Wainwright raised its price target from USD 58.00 to USD 65.00 on October 15, 2026, according to Markets Insider.

Target rises after analyst review

The target increase kept a Buy rating and followed Liquidia's settlement with United Therapeutics, which resolved six lawsuits, as the same Markets Insider report stated. The analyst view places attention on YUTREPIA and Liquidia's pulmonary arterial hypertension business.

Revenue beat the second-quarter estimate

Liquidia reported USD 171.68 million in revenue for the second quarter of 2026, compared with a USD 168.48 million consensus estimate, while diluted earnings per share were USD 0.74 against USD 0.76 expected, according to MarketBeat. Finance statements put operating profit at USD 85.52 million and the operating margin at 50.00 percent for the same quarter.

What comes with the November date?

Liquidia is estimated to report third-quarter 2026 results on November 2, 2026, before the market opens, with a conference call at 8:30 a.m. ET, according to MarketBeat. The same estimate calls for USD 214.18 million in revenue and USD 0.92 in earnings per share, versus USD 54.34 million and minus USD 0.04 in the year-earlier quarter.

Liquidia stays below its yearly high

Liquidia's primary Nasdaq quote was USD 36.11 at 12:40 p.m. ET on October 20, 2026. Its market capitalization was USD 3.2 billion, while the 52-week range was USD 21.94 to USD 93.61. The company develops therapies for rare cardiopulmonary diseases and identifies YUTREPIA and L606 as key programs on its Liquidia investor page.

Stock position and investor dates

The target change and the November reporting date give investors two separate reference points: valuation expectations and the next operating update. Liquidia held USD 284.18 million in cash at June 30, 2026, while operating profit reached USD 85.52 million in the second quarter.

Price and next update

The euro quotation stood at EUR 32.22 at Lang & Schwarz on October 20, 2026 at 6:35 p.m. CEST. The next scheduled event is the estimated third-quarter results release on November 2, 2026. The further course of trading is shown by the continuously updated real-time quote of Liquidia stock.